Not to be confused with hesperidin.

Hesperadin is an aurora kinase inhibitor.

The small molecule inhibits chromosome alignment and segregation by limiting the function of mitotic kinases Aurora B and Aurora A. Hesperadin causes cells to enter anaphase much faster, sometimes before the chromosomes are properly bi-oriented.[1]

Hesperadin, like other miotic inhibitors, limits and sometimes can stop the process of mitosis in cells. For this reason, some have considered hesperadin's potential as a cancer-preventing drug.[2]

Hesperadin works as an inhibitor, attaching to the active sites of Aurora A and Aurora B kinases.[2]

References

  1. ^ Hauf, Silke; Cole, Richard W.; LaTerra, Sabrina; Zimmer, Christine; Schnapp, Gisela; Walter, Rainer; Heckel, Armin; van Meel, Jacques; Rieder, Conly L. (2003-04-28). "The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint". The Journal of Cell Biology. 161 (2): 281–294. doi:10.1083/jcb.200208092. ISSN 0021-9525. PMC 2172906. PMID 12707311.
  2. ^ a b Jetton, Neal; Rothberg, Karen G.; Hubbard, James G.; Wise, John; Li, Yan; Ball, Haydn L.; Ruben, Larry (April 2009). "The cell cycle as a therapeutic target againstTrypanosoma brucei: Hesperadin inhibits Aurora kinase-1 and blocks mitotic progression in bloodstream forms". Molecular Microbiology. 72 (2): 442–458. doi:10.1111/j.1365-2958.2009.06657.x. ISSN 0950-382X. PMC 2697958. PMID 19320832.